Status:

ACTIVE_NOT_RECRUITING

Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Lead Sponsor:

Arcus Biosciences, Inc.

Collaborating Sponsors:

Taiho Pharmaceutical Co., Ltd.

Conditions:

Metastatic Pancreatic Ductal Adenocarcinoma

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

The purpose of this study is to compare overall survival of quemliclustat, nab-paclitaxel and gemcitabine versus placebo, nab-paclitaxel and gemcitabine in all randomized patients.

Eligibility Criteria

Inclusion

  • Have histologically or cytologically confirmed PDAC that is metastatic.
  • Have not been previously treated for PDAC in the metastatic setting.
  • Prior neoadjuvant and/or adjuvant therapy for PDAC is permitted if completed at least 12 months before randomization.
  • Prior palliative radiotherapy is allowed if completed at least 2 weeks prior to randomization and AEs have resolved to Grade 1 or less before randomization.
  • Prior and/or placement of a biliary stent/tube is permitted if any treatment-related AEs have improved to Grade ≤ 1 and the patient is not exhibiting any signs/symptoms of biliary obstruction.
  • Eastern Cooperative Oncology Group PS of 0 to 1.
  • At least 1 target lesion measurable by computed tomography (CT)/magnetic resonance imaging (MRI) per RECIST v1.1. not within a field of prior radiation therapy.

Exclusion

  • Previously treated for locally advanced, unresectable PDAC.
  • History of brain metastases or leptomeningeal metastases.
  • Prior treatment with a CD73 antagonist or inhibitor.
  • Underlying medical conditions that, in the investigator or sponsor's opinion, will make the administration of study-specified therapy hazardous
  • NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Key Trial Info

Start Date :

December 13 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

November 30 2030

Estimated Enrollment :

610 Patients enrolled

Trial Details

Trial ID

NCT06608927

Start Date

December 13 2024

End Date

November 30 2030

Last Update

December 23 2025

Active Locations (125)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 32 (125 locations)

1

Mayo Clinic Arizona - Phoenix Campus

Phoenix, Arizona, United States, 85054

2

University of Arizona Cancer Center

Tucson, Arizona, United States, 85724

3

University of California San Diego Health

La Jolla, California, United States, 92093

4

Cancer & Blood Specialty Clinic - Los Alamitos

Los Alamitos, California, United States, 90720